Gapping up
In reaction to earnings/guidance:
- UBER +5.2%, AZO +1.6%, HRI +1.5% (raised FY21 adj. EBITDA guidance, provided targets for 2022, and outlined strategic initiatives), AXTA +0.9% (lowered Q3 net sales guidance and withdrew FY21 guidance)
Select ETFs showing strength:
- DIA +0.8%, IWM +0.8%, SPY +0.7%, QQQ +0.7%
Other news:
- VRDN +27% (prices offering of 6,185,454 shares of common stock at $11.00 per share)
- SGEN +5.6% (co and Genmab [GMAB] announced FDA accelerated approval for TIVDAK)
- OEG +5.5% (awarded new telecom project by Charter Communications [CHTR])
- RDS.A +5.2% (agreed to sell Permian basin assets to ConocoPhillips [COP] for $9.5 bln)
- ORIC +4.8% (provides update on its CD73 inhibitor program; FDA cleared the company's IND for ORIC-533 to proceed into a first-in-human clinical trial)
- APRE +3.5% (presented data from Phase 1/2 trial of eprenetapopt in advanced solid tumors)
- SDC +3.5% (plans to expand into France at start of Q4)
- TECK +3% (provides guidance update ahead of investor presentation)
- ROOT +2.8% (appointed Daniel Rosenthal as Chief Revenue and Operating Officer)
- GMAB +2.6% (co and Seagen [SGEN] announced FDA accelerated approval for TIVDAK in previously treated recurrent or metastatic cervical cancer)
- USB +1.4% (to acquire MUFG Union Bank for $8 bln)
- AA +1.3% (plans to restart 268,000 metric tons per year of aluminum capacity at Alumar smelter in São Luís, Brazil, which has been fully curtailed since 2015)
- WWR +1.2% (provides progress update on definitive feasibility study)
- SRAD +1.1% (announced that Michael Jordan will serve as a special advisor to co's board and is increasing his investment in co)
- GOED +1% (Issues Letter to Stockholders Regarding Leadership Team's Vision and Strategy)
Analyst comments:
- ATTO +4% (upgraded to Neutral from Sell at Goldman)
- GLOB +1.6% (upgraded to Buy from Neutral at Goldman)